Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629758 · ClinicalTrials.gov registry record · Phase 1
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
A Phase 1 study of Neoplasms by Site, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 5
- Study locations
NCT01629758 is a Phase 1 study of Neoplasms by Site that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants, below the 509-participant average among 11 other Neoplasms by Site trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01629758, a Phase 1 study of Neoplasms by Site, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the combination.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Denenicokin
Study Locations (5)
Arizona
- Oncology Research Associates, Pllc D/B/A - Scottsdale
Connecticut
- Yale University School Of Medicine - New Haven
Florida
- Moffitt Cancer Center - Tampa
Maryland
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins - Baltimore
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2012-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01629758
The ClinicalTrials.gov registry entry for NCT01629758 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 509-participant average among 11 other Neoplasms by Site trials with a reported enrollment target (94% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms by Site appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT01629758 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT01629758 about?
NCT01629758 is a clinical study titled "Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors". The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the combination.
What is the current status of trial NCT01629758?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2012-06. Estimated completion is 2014-12.
What conditions does trial NCT01629758 study?
This clinical trial studies the following conditions: Neoplasms by Site.
What interventions are being tested in trial NCT01629758?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Denenicokin (BIOLOGICAL).
Who is sponsoring clinical trial NCT01629758?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01629758 being conducted?
This trial has 5 study locations across Arizona, Connecticut, Florida, Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms by Site
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
RECRUITING · Phase 1
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Real World Registry for Use of the Ion Endoluminal System
RECRUITING
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.